• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials
patient education

Sickle Cell Disease Health Disparities

key information

source: CDC Foundation

year: N/A

summary/abstract:

Sickle cell disease (SCD) is the world’s most common genetic disease, affecting approximately 100,000 people in the United States. As a group, people with SCD experience worse health outcomes compared to other diseases and have access to fewer health resources. This lack of equality is termed a health disparity.

Through a partnership with the Centers for Disease Control and Prevention’s Division of Blood Disorders, Tracking California and the Georgia Health Policy Center, the CDC Foundation is implementing the Sickle Cell Data Collection (SCDC) program to collect health information about people with SCD to study long-term trends in diagnosis, treatment and healthcare access. The SCDC program aims to use study findings to inform policy and health care changes that decrease health disparities for people with SCD.

The project is receiving funding support from Pfizer Inc., Bioverativ and Global Blood Therapeutics and is active in California and Georgia. Additional support is needed to expand the program to all of the United States to improve the disparate state of SCD.

read more

expertly curated content related to this topic

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close